No results for ‘’
Neuland Laboratories Ltd
₹16624
(0.99%)
Wed, 27 May 2026, 04:37 pm
Health Technology
Pharmaceuticals: Major
24.5KNeuland Laboratories Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 10.63 | 10.14 | 7.36 | 4.13 | 0 | 12.09 | 15.38 | 5.18 | 7.42 | 17.85 | 22.76 | 28.21 | 52.07 | 51.62 | 22.43 | 33.22 | 20.64 | 14.12 | 26.86 | 59.57 |
| Price to book ratio | 1.25 | 1.54 | 1.22 | 0.65 | 0.80 | 0.86 | 0.52 | 0.72 | 1.61 | 1.83 | 3.33 | 2.42 | 1.13 | 1.24 | 0.51 | 3.41 | 1.57 | 2.32 | 6.28 | 10.16 |
| Price to sales ratio | 0.41 | 0.45 | 0.38 | 0.16 | 0.20 | 0.16 | 0.09 | 0.16 | 0.43 | 0.62 | 1.25 | 2.33 | 1.23 | 1.31 | 0.49 | 2.90 | 1.41 | 1.96 | 5.25 | 10.66 |
| Price to cash flow ratio | 7.72 | 0 | 12.28 | 4.44 | 0 | 6.81 | 1.79 | 19.41 | 7.18 | 0 | 21.57 | 74.01 | 0 | 18.29 | 9.43 | 15.43 | 28.08 | 10.20 | 31.52 | 48.47 |
| Enterprise value | 1.01B | 1.61B | 2.08B | 2.38B | 2.75B | 2.83B | 2.57B | 2.84B | 3.88B | 4.66B | 7.94B | 14.94B | 9.23B | 10.35B | 5.73B | 28.35B | 15.34B | 23.78B | 80.37B | 152.85B |
| Enterprise value to EBITDA ratio | 1.45 | 8.46 | 10.05 | 9.34 | 10.48 | 6.31 | 4.93 | 4.63 | 5.30 | 7.13 | 10.12 | 15.53 | 25.14 | 24.15 | 6.84 | 20.62 | 11.88 | 8.83 | 18.02 | 48.69 |
| Debt to equity ratio | 0.79 | 1.31 | 1.95 | 2.64 | 3.41 | 3.17 | 2.89 | 2.14 | 1.53 | 1.16 | 0.98 | 0.35 | 0.57 | 0.33 | 0.37 | 0.23 | 0.29 | 0.13 | 0.07 | 0.10 |
| Return on equity % | 0 | 16.14 | 17.69 | 16.51 | -9.58 | 7.45 | 3.42 | 15.76 | 23.96 | 11.18 | 15.70 | 12.80 | 3.10 | 2.62 | 2.30 | 10.78 | 7.85 | 17.83 | 26.36 | 18.53 |
Neuland Laboratories Ltd Enterprise Value
The Neuland Laboratories Ltd Enterprise Value is a key financial metric used by investors to evaluate Neuland Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Neuland Laboratories Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Neuland Laboratories Ltd (NSE: NEULANDLAB, BSE: 524558) is currently trading at ₹16624, with a market capitalization of ₹215.2B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Neuland Laboratories Ltd Enterprise Value is essential for fundamental analysis.
Neuland Laboratories Ltd Enterprise Value Current Value
The current Neuland Laboratories Ltd Enterprise Value stands at 152.85B.
The latest Neuland Laboratories Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Neuland Laboratories Ltd Enterprise Value Historical Trend
The Neuland Laboratories Ltd Enterprise Value has shown the following historical trend:
- 2024: 152.85B
- 2023: 80.37B
- 2022: 23.78B
- 2021: 15.34B
- 2020: 28.35B
The recent rise in Neuland Laboratories Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Neuland Laboratories Ltd Enterprise Value Indicates for Investors
The Neuland Laboratories Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Neuland Laboratories Ltd.
Neuland Laboratories Ltd Enterprise Value Analysis Summary
The Neuland Laboratories Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Neuland Laboratories Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Neuland Laboratories Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.